SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AL-S Pharma Reports AP-101 Weight Data, Outlines ALS Phase 3 Trial

AL-S Pharma reported new Phase 2 post-hoc weight data for AP-101 and outlined a Phase 3 clinical trial in ALS at the 2026 NEALS Annual Meeting.

Related stories